Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2024 | Aug. 08, 2024 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Jun. 30, 2024 | |
Document Fiscal Year Focus | 2024 | |
Document Fiscal Period Focus | Q2 | |
Trading Symbol | TCRX | |
Entity Registrant Name | TSCAN THERAPEUTICS, INC. | |
Entity Central Index Key | 0001783328 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Shell Company | false | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity File Number | 001-40603 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 82-5282075 | |
Entity Address, Address Line One | 830 Winter Street | |
Entity Address, State or Province | MA | |
Entity Address, City or Town | Waltham | |
Entity Address, Postal Zip Code | 02451 | |
City Area Code | 857 | |
Local Phone Number | 399-9500 | |
Title of 12(b) Security | Voting Common Stock, $0.0001 par value per share | |
Security Exchange Name | NASDAQ | |
Voting Common Stock | ||
Document Information [Line Items] | ||
Entity Common Stock, Shares Outstanding | 48,697,282 | |
Non-voting Common Stock | ||
Document Information [Line Items] | ||
Entity Common Stock, Shares Outstanding | 4,276,588 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 |
Current assets: | ||
Cash and cash equivalents | $ 242,159 | $ 133,359 |
Marketable securities | 55,517 | 58,685 |
Prepaid expenses and other current assets | 1,854 | 2,193 |
Total current assets | 299,530 | 194,237 |
Property and equipment, net | 7,615 | 7,742 |
Right-of-use assets | 60,949 | 63,492 |
Restricted cash | 5,031 | 5,031 |
Long-term deposit and other assets | 1,746 | 1,647 |
Total assets | 374,871 | 272,149 |
Current liabilities: | ||
Accounts payable | 3,110 | 2,374 |
Accrued expenses and other current liabilities | 10,808 | 10,716 |
Operating lease liability, current portion | 3,614 | 3,246 |
Deferred revenue, current portion | 10,704 | 10,137 |
Current portion of long-term debt | 10,336 | 3,347 |
Total current liabilities | 38,572 | 29,820 |
Deferred revenue, net of current portion | 3,955 | 5,622 |
Operating lease liability, net of current portion | 57,011 | 59,140 |
Long-term debt and accrued interest | 20,112 | 26,700 |
Total liabilities | 119,650 | 121,282 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023 | 0 | 0 |
Additional paid-in capital | 564,615 | 398,459 |
Accumulated deficit | (309,400) | (247,597) |
Total stockholders' equity | 255,221 | 150,867 |
Total liabilities and stockholders' equity | 374,871 | 272,149 |
Voting Common Stock | ||
Stockholders' equity: | ||
Common stock | 5 | 4 |
Non-voting Common Stock | ||
Stockholders' equity: | ||
Common stock | $ 1 | $ 1 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Jun. 30, 2024 | Dec. 31, 2023 |
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Voting Common Stock | ||
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 300,000,000 | 300,000,000 |
Common stock, shares issued | 48,656,158 | 43,552,941 |
Common stock, shares outstanding | 48,656,158 | 43,552,941 |
Non-voting Common Stock | ||
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 10,000,000 | 10,000,000 |
Common stock, shares issued | 4,276,588 | 4,276,588 |
Common stock, shares outstanding | 4,276,588 | 4,276,588 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Revenue | ||||
Collaboration and license revenue | $ 536 | $ 3,148 | $ 1,102 | $ 9,951 |
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | Collaboration and license revenue | Collaboration and license revenue | Collaboration and license revenue | Collaboration and license revenue |
Operating expenses: | ||||
Research and development | $ 26,877 | $ 21,227 | $ 51,734 | $ 43,006 |
General and administrative | 7,773 | 6,531 | 14,855 | 14,298 |
Total operating expenses | 34,650 | 27,758 | 66,589 | 57,304 |
Loss from operations | (34,114) | (24,610) | (65,487) | (47,353) |
Other (expense) income: | ||||
Interest and other income, net | 3,405 | 1,534 | 5,595 | 2,670 |
Interest expense | (952) | (969) | (1,911) | (1,925) |
Total other income | 2,453 | 565 | 3,684 | 745 |
Net loss | $ (31,661) | $ (24,045) | $ (61,803) | $ (46,608) |
Net loss per share, basic | $ (0.28) | $ (0.51) | $ (0.59) | $ (1.3) |
Net loss per share, diluted | $ (0.28) | $ (0.51) | $ (0.59) | $ (1.3) |
Weighted average common shares outstanding- basic | 113,425,357 | 47,208,664 | 104,150,625 | 35,717,309 |
Weighted average common shares outstanding-diluted | 113,425,357 | 47,208,664 | 104,150,625 | 35,717,309 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | Total | Non-voting Common Stock | Voting Common Stock | Common Stock Non-voting Common Stock | Common Stock Voting Common Stock | Additional Paid-In Capital | Accumulated Deficit |
Balances at Dec. 31, 2022 | $ 99,434 | $ 1 | $ 2 | $ 257,810 | $ (158,379) | ||
Balances, shares at Dec. 31, 2022 | 5,143,134 | 19,082,820 | |||||
Exercise of stock options | 682 | 682 | |||||
Exercise of stock options, shares | 305,678 | ||||||
Issuance of common stock, net of offering costs | 42,414 | $ 2 | 42,412 | ||||
Issuance of common stock, net of offering costs, shares | 23,287,134 | ||||||
Issuance of pre-funded warrants, net of offering costs | 92,318 | 92,318 | |||||
Conversion of non-voting common stock to voting common stock | (866,546) | 866,546 | |||||
Stock-based compensation expense | 2,367 | 2,367 | |||||
Net loss | (46,608) | (46,608) | |||||
Balances at Jun. 30, 2023 | 190,607 | $ 1 | $ 4 | 395,589 | (204,987) | ||
Balances, shares at Jun. 30, 2023 | 4,276,588 | 43,542,178 | |||||
Balances at Mar. 31, 2023 | 78,018 | $ 1 | $ 2 | 258,957 | (180,942) | ||
Balances, shares at Mar. 31, 2023 | 4,745,225 | 19,480,729 | |||||
Exercise of stock options | 682 | 682 | |||||
Exercise of stock options, shares | 305,678 | ||||||
Issuance of common stock, net of offering costs | 42,414 | $ 2 | 42,412 | ||||
Issuance of common stock, net of offering costs, shares | 23,287,134 | ||||||
Issuance of pre-funded warrants, net of offering costs | 92,318 | 92,318 | |||||
Conversion of non-voting common stock to voting common stock | (468,637) | 468,637 | |||||
Stock-based compensation expense | 1,220 | 1,220 | |||||
Net loss | (24,045) | (24,045) | |||||
Balances at Jun. 30, 2023 | 190,607 | $ 1 | $ 4 | 395,589 | (204,987) | ||
Balances, shares at Jun. 30, 2023 | 4,276,588 | 43,542,178 | |||||
Balances at Dec. 31, 2023 | 150,867 | $ 1 | $ 4 | 398,459 | (247,597) | ||
Balances, shares at Dec. 31, 2023 | 4,276,588 | 43,552,941 | 4,276,588 | 43,552,941 | |||
Exercise of stock options | 442 | 442 | |||||
Exercise of stock options, shares | 145,149 | ||||||
Issuance of common stock, net of offering costs | 33,131 | $ 1 | 33,130 | ||||
Issuance of common stock, net of offering costs, shares | 4,958,068 | ||||||
Issuance of pre-funded warrants, net of offering costs | 128,272 | 128,272 | |||||
Stock-based compensation expense | 4,312 | 4,312 | |||||
Net loss | (61,803) | (61,803) | |||||
Balances at Jun. 30, 2024 | 255,221 | $ 1 | $ 5 | 564,615 | (309,400) | ||
Balances, shares at Jun. 30, 2024 | 4,276,588 | 48,656,158 | 4,276,588 | 48,656,158 | |||
Balances at Mar. 31, 2024 | 122,967 | $ 1 | $ 4 | 400,701 | (277,739) | ||
Balances, shares at Mar. 31, 2024 | 4,276,588 | 43,628,149 | |||||
Exercise of stock options | 183 | 183 | |||||
Exercise of stock options, shares | 69,941 | ||||||
Issuance of common stock, net of offering costs | 33,131 | $ 1 | 33,130 | ||||
Issuance of common stock, net of offering costs, shares | 4,958,068 | ||||||
Issuance of pre-funded warrants, net of offering costs | 128,272 | 128,272 | |||||
Stock-based compensation expense | 2,329 | 2,329 | |||||
Net loss | (31,661) | (31,661) | |||||
Balances at Jun. 30, 2024 | $ 255,221 | $ 1 | $ 5 | $ 564,615 | $ (309,400) | ||
Balances, shares at Jun. 30, 2024 | 4,276,588 | 48,656,158 | 4,276,588 | 48,656,158 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Cash flows from operating activities: | ||
Net loss | $ (61,803) | $ (46,608) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation expense | 2,370 | 2,795 |
Accretion of marketable securities | (846) | |
Non-cash interest expense related to note payable | 401 | 432 |
Stock-based compensation | 4,312 | 2,367 |
Changes in current assets and liabilities: | ||
Accounts receivable | (31,926) | |
Prepaid expenses and other assets | 240 | 1,728 |
Right-of-use assets and lease liabilities, net | 605 | 240 |
Accounts payable | (14) | 862 |
Accrued expense and other liabilities | 343 | 1,520 |
Deferred revenue | (1,100) | 22,981 |
Net cash used in operating activities | (55,492) | (45,609) |
Cash flows from investing activities: | ||
Purchases of property and equipment | (1,567) | (1,258) |
Purchases of marketable securities | (57,133) | |
Maturities of marketable securities | 61,147 | |
Net cash provided by (used in) investing activities | 2,447 | (1,258) |
Cash flows from financing activities: | ||
Proceeds from issuance of common stock, net of offering costs | 33,131 | 42,600 |
Proceeds from issuance of pre-funded warrants, net of offering costs | 128,272 | 92,394 |
Proceeds from exercise of stock options | 442 | 682 |
Net cash provided by financing activities | 161,845 | 135,676 |
Net increase (decrease) in cash, cash equivalents and restricted cash | 108,800 | 88,809 |
Cash, cash equivalents, and restricted cash - beginning of period | 138,390 | 125,064 |
Cash, cash equivalents, and restricted cash - end of period | 247,190 | 213,873 |
Summary of cash, cash equivalents and restricted cash reported within the consolidated balance sheets: | ||
Cash and cash equivalents | 242,159 | 208,842 |
Restricted cash | 5,031 | 5,031 |
Total cash, cash equivalents, and restricted cash | 247,190 | 213,873 |
Supplemental disclosure of cash flow information: | ||
Cash paid for interest | 1,510 | 1,502 |
Supplemental disclosure of non-cash investing and financing activities: | ||
Purchase of property and equipment in accounts payable and accrued liabilities | $ 977 | 87 |
Issuance costs included in accounts payable and accrued liabilities | $ 262 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Pay vs Performance Disclosure | ||||
Net Income (Loss) | $ (31,661) | $ (24,045) | $ (61,803) | $ (46,608) |
Insider Trading Arrangements
Insider Trading Arrangements | 6 Months Ended |
Jun. 30, 2024 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Rule 10b5-1 Arrangement Modified | false |
Non-Rule 10b5-1 Arrangement Modified | false |
Nature of Business and Basis of
Nature of Business and Basis of Presentation | 6 Months Ended |
Jun. 30, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of Business and Basis of Presentation | 1. Nature of Business and Basis of Presentation Nature of Business TScan Therapeutics, Inc. and its wholly-owned subsidiary, TScan Securities Corporation (the Company), is a biotechnology company that was incorporated in Delaware on April 17, 2018 and has a principal place of business in Waltham, Massachusetts. The Company is focused on developing a pipeline of TCR-T therapy candidates for the treatment of patients with cancer. Basis of Presentation The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (the SEC) regarding interim financial reporting, and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Management believes that the interim financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position, results of its operations and cash flows. The condensed consolidated financial statements include the accounts of TScan Therapeutics, Inc. and its subsidiary, TScan Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. The results for the three and six months ended June 30, 2024, are not necessarily indicative of results to be expected for the year ending December 31, 2024, any other interim periods, or any future year or period. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 6, 2024. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included. Risks, Uncertainties and Going Concern The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, successful development of technology, obtaining additional funding, protection of proprietary technology, compliance with government regulations, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates and the ability to successfully market any products that receive approval, fluctuations in operating results, economic pressure impacting therapeutic pricing, dependence on key personnel, risks associated with changes in technologies, development by competitors of technological innovations and the ability to scale manufacturing to large scale production. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from sales. The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has primarily funded its operations with proceeds from sales of capital stock, payments received under its license and collaboration agreements and issuance of a debt facility to K2 HealthVentures LLC (K2HV). Since its inception, the Company has incurred recurring losses, including net losses of $ 61.8 million and $ 46.6 million for the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, the Company had an accumulated deficit of $ 309.4 million. The Company expects to continue to generate operating losses in the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2024, will be sufficient to fund the Company’s operations for at least the next 12 months from the date of the issuance of these financial statements. Emerging Growth Company Status The Company qualifies as “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act) and has elected to “opt in” to the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for nonpublic companies. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2024 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies The accounting policies of the Company are set forth in Note 2 to the consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, the accounting policies followed by the Company for interim financial reporting are consistent with the accounting policies therein. Recent Issued Accounting Pronouncements Not Yet Effective In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, “Segment Reporting - Improvements to Reportable Segment Disclosures.” The ASU requires disclosure of incremental segment information on an annual and interim basis and also requires companies with a single reportable segment to provide all disclosures required by this ASU and all existing segment disclosures in Accounting Standard Codification (“ASC”) 280, “Segment Reporting.” The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” This ASU updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid by jurisdiction. This ASU is effective for annual periods beginning after December 15, 2024, and is applicable to the Company’s fiscal year beginning January 1, 2025, with early application permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures. |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2024 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | 3. Fair Value M easurements The following tables set forth by level, within the fair value hierarchy, the assets carried at fair value (in thousands): Fair value measurements at June 30, 2024 using Active Observable Unobservable Total Cash Equivalents: Money market funds $ 73,543 $ - $ - $ 73,543 Government securities 161,061 - - 161,061 Marketable Securities: Government securities 55,517 - - 55,517 Total $ 290,121 $ - $ - $ 290,121 Fair value measurements at December 31, 2023 using Active Observable Unobservable Total Cash Equivalents: Money market funds $ 52,299 $ - $ - $ 52,299 Government securities 76,483 - - 76,483 Marketable Securities: Government securities 58,685 - - 58,685 Total $ 187,467 $ - $ - $ 187,467 Money market funds and government securities are valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. There were no transfers among Level 1, Level 2, or Level 3 categories in the periods presented. Assets and Liabilities Not Carried at Fair Value The Company's long-term debt is carried at amortized cost. The fair value of the long-term debt was estimated to be $ 38.5 million and $ 38.4 million at June 30, 2024 and December 31, 2023, respectively. Fair value was determined using a convertible bond model using a binomial lattice approach. We classified the long-term debt within Level 3 of the fair value hierarchy because the fair value is derived using significant unobservable inputs, which include discount rates and volatility. The carrying value of cash, accounts payable and accrued expenses that are reported on the condensed consolidated balance sheets approximate their fair value due to the short-term nature of these assets and liabilities. |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 6 Months Ended |
Jun. 30, 2024 | |
Payables and Accruals [Abstract] | |
Accrued Expenses and Other Current Liabilities | 4. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): June 30, December 31, 2024 2023 Accrued research and development $ 5,465 $ 3,537 Accrued employee compensation and benefits 3,525 5,478 Accrued consulting and professional services 719 1,026 Accrued legal services and license fee 852 250 Other 247 425 Total accrued expenses and other current liabilities $ 10,808 $ 10,716 |
Stockholders' Equity
Stockholders' Equity | 6 Months Ended |
Jun. 30, 2024 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity | 5. Stockholders' Equity ATM Program On May 16, 2023, the Company entered into a sales agreement (the Sales Agreement) with Wedbush Securities, Inc. (Wedbush), as sales agent, pursuant to which the Company could offer, issue and sell up to an aggregate amount of $ 75.0 million of shares of the Company's voting common stock, par value $ 0.0001 per share (Voting Common Stock), from time to time in “at-the-market” (ATM) offerings during the term of the Sales Agreement under a registration statement on Form S-3 (File No. 333-268260) filed with the SEC, which was declared effective on May 16, 2023. No Voting Common Stock has been sold under this Sales Agreement to date. Equity Offerings On June 1, 2023, the Company completed an underwritten public offering resulting in the issuance and sale of (a) 23,287,134 shares of Voting Common Stock, at a price of $ 2.00 per share, and (b) pre-funded warrants (Pre-Funded Warrants) to purchase up to 47,010,526 shares of the Voting Common Stock, at a price of $ 1.9999 per warrant with an exercise price of $ 0.0001 per share. The Company received aggregate net proceeds of $ 134.7 million after deducting underwriting discounts, commissions and other offering expenses, with $ 42.4 million allocated to the Voting Common Stock and $ 92.3 million allocated to Pre-Funded Warrants. On April 24, 2024, the Company completed an underwritten public offering resulting in the issuance and sale of (a) 4,958,068 shares of Voting Common Stock, including the partial exercise of the underwriters’ option to purchase 2,485,487 additional shares of Voting Common Stock, at the closing market price on April 16, 2024, of $ 7.13 per share, and (b) Pre-Funded Warrants to purchase up to 18,577,419 shares of the Voting Common Stock, at a price of $ 7.1299 per warrant with an exercise price of $ 0.0001 per share. The Company received aggregate net proceeds of approximately $ 161.4 million after deducting underwriting discounts, commissions and other offering expenses , with $ 33.1 million allocated to the Voting Common Stock and $ 128.3 million allocated to Pre-Funded Warrants. The Pre-Funded Warrants are immediately exercisable subject to certain ownership limitations, have an exercise price of $ 0.0001 per share, may be exercised at any time and do not expire. The Pre-Funded Warrants were determined to be equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company’s common stock and meet the equity classification criteria. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return. As such, proceeds received from the issuance from the Pre-Funded Warrants were recorded as a component of stockholders’ equity within additional paid-in capital. As of June 30, 2024 , no Pre-Funded Warrants have been exercised. |
Collaboration and License Agree
Collaboration and License Agreements | 6 Months Ended |
Jun. 30, 2024 | |
Collaboration And License Agreements [Abstract] | |
Collaboration and License Agreements | 6. Collaboration and License Agreements Novartis In March 2020 , the Company entered into a Collaboration and License Agreement (the Novartis Agreement) with Novartis Institutes For Biomedical Research, Inc. (Novartis) to collaborate on their research efforts to discover and develop novel TCR-T therapies. The Novartis Agreement concluded during the quarter ended March 31, 2023 during which, the Company recognized $ 5.8 million of revenue . Amgen On May 8, 2023 , the Company entered into a Collaboration Agreement with Amgen Inc. (the Amgen Agreement) to identify antigens recognized by T cells in patients with Crohn’s disease in accordance with a research plan. Under the terms of the Agreement, Amgen will retain all global development and commercialization rights, as well as an option to expand the collaboration to include target discovery for ulcerative colitis, under certain pre-specified terms. The proceeds from the Amgen Agreement include an upfront payment of $ 30 million, which was collected in July 2023. In addition, the Company is eligible to earn success-based milestone payments of over $ 500 million, based upon the achievement of certain clinical development and commercial milestones, as well as tiered single-digit royalty payments on net sales of products developed from the collaboration, subject to reductions set forth in the Amgen Agreement. The Company concluded that Amgen meets the definition of a customer, as the Company is delivering research and development activities and a license of intellectual property. The Company identified performance obligations for research and development activities, the license, data reporting and participation in joint steering and research committees, which were determined to be a single combined performance obligation due to the services and licenses being highly interrelated. For a certain time period during the term of the Amgen Agreement, Amgen has an option to add targets to the collaboration for payments specified in the agreement. Pursuant to the Amgen Agreement, the option for Amgen to select additional targets and to license, develop, and commercialize targets is not a performance obligation at the outset as these are customer options that do not represent material rights. The Company looked to the promises in the arrangement to determine the method of recognition that best depicted the transfer of the services and the satisfaction of the combined performance obligations. The Company concluded that the performance of the research services over the expected research term was the predominant promise within the performance obligation. The Company will recognize the revenue associated with the performance obligation using an input method. The method of measuring progress towards delivery of the services incorporates actual internal and external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. Changes in estimates of total internal and external costs expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment. As costs are incurred, the Company will recognize revenue over time. At this time, it is estimated that the research term will be approximately three years . The Company determined the $ 30.0 million upfront payment to be the entirety of the consideration to be included in the transaction price as of the onset of the arrangement. The option to add additional targets was not included in the transaction price as they were assessed to be improbable at this time. The potential milestone and royalty payments that the Company is eligible to receive were also excluded from the transaction price, as all milestone and royalty amounts were fully constrained based on the assessed probability of achievement. The Company will continue to assess the probability of the option to add additional targets and the probability of milestone achievement throughout the research term and will adjust the consideration in the contract accordingly. The $ 30.0 million up-front payment was invoiced in June 2023 and was fully collected in July 2023. During the three and six months ended June 30, 2024 and 2023, the Company recognized $ 0.5 million, $ 1.1 million, $ 3.1 million, and $ 3.1 million, respectively, of revenue associated with the Amgen Agreement. As of June 30, 2024, the Company recorded $ 14.7 million of deferred revenue, of which $ 4.0 million is classified as long-term. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2024 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 7. Commitments and Contingencies Leases The Company leases office space under non-cancelable operating lease agreements. There have been no material changes to the Company's leases during the period ended June 30, 2024. Brigham and Women’s License Agreement The Company obtained the worldwide exclusive license to its foundational technology from the Brigham and Women’s Hospital, Inc. (BWH). The license, as amended, grants worldwide exclusive use to the patent underlying the TargetScan technology in exchange for fees including development milestones and various royalties on product sales should they occur in the future. Royalty Agreement In June 2018, the Company amended and restated an existing royalty agreement with one of its founders. Under the amended and restated royalty agreement, the Company agreed to pay the founder an aggregate royalty of 1 % of net sales of any product sold by the Company or by any of its direct or indirect licensees for use in the treatment of any disease or disorder covered by a pending patent application or issued patent held or controlled by the Company as of the last date that the founder was providing services to the Company as a director or consultant under a written agreement in perpetuity. Royalties are payable with respect to each applicable product for a defined period of time set forth in the royalty agreement. The founder assigned his rights and obligations under the royalty agreement to one of his affiliated entities in January 2021. |
Loan and Security Agreement
Loan and Security Agreement | 6 Months Ended |
Jun. 30, 2024 | |
Debt Disclosure [Abstract] | |
Loan and Security Agreement | 8. Loan and Security Agreement On September 9, 2022 (the Closing Date), the Company entered into a Loan and Security Agreement (the Loan Agreement) with K2HV, pursuant to which convertible term loans in an aggregate principal amount of up to $ 60 million is available to the Company in three tranches, subject to certain terms and conditions. The Company drew the first tranche of $ 30 million from K2HV on the Closing Date. The Company had the option to draw the second tranche of $ 10 million upon the achievement of certain financial and clinical milestones and an uncommitted third tranche of $ 20 million may be funded by joint agreement of the Company and K2HV. The Company's option to draw on the second tranche was not exercised and expired on June 1, 2024. On the Closing Date, the Company paid a facility fee of $ 0.4 million to K2HV and is subject to an additional 1 % of the principal amount of any amount drawn on the third tranche. The term loans mature on September 1, 2026 (the Maturity Date) and will be subject to interest-only payments for 24 months, which can be extended to 36 months upon achievement of certain financial and clinical milestones, following which the term loans will amortize in equal monthly installments until maturity. The Company has the ability to repay the loan at any time either in cash or in shares, subject to applicable premiums as specified in the Loan Agreement. The term loans will accrue interest at a per annum rate equal to the greater of (i) 8.75 % and (ii) the sum of (A) the prime rate (as last quoted in The Wall Street Journal) and (B) 4.75 %, subject to a cap of 9.90 %. At June 30, 2024, the applicable interest rate is 9.90 %. The lenders may elect at any time following the closing prior to the payment in full of the term loans to convert any portion of the principal amount of the term loans then outstanding into shares of the Company's common stock. The first tranche of the loan is convertible at the option of K2HV at a conversion price of $ 4.785 per share and future tranches will be convertible as specified in the agreement, provided that, such price shall be subject to the applicable conversion price floor and other adjustments in accordance with the Loan Agreement. The embedded conversion option meets the derivative accounting scope exception since the embedded conversion option is indexed to the Company’s own common stock and qualifies for classification within stockholders’ equity. The Company has the option to prepay all, but not less than all, of the outstanding principal balance of the term loans under the Loan Agreement subject to a prepayment fee ranging from 4 % to 1 % depending upon when the prepayment occurs. The Company is obligated to pay a final fee equal to 6.00 % of the aggregate amount of the term loans funded (the Exit Fee), to occur upon the earliest of (i) the maturity date, (ii) the acceleration of the term loans, and (iii) the prepayment of the term loans. If, upon equity conversion, K2HV receives gross proceeds in an amount equal to at least 1.5 multiplied by the principal amount converted from the sale or other disposition of such Conversion Shares (as defined in the Loan Agreement), then as to such principal amount, the Exit Fee will be reduced to zero. The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets (other than intellectual property), subject to certain exceptions. The Loan Agreement contains customary representations and warranties, and also includes customary events of default, including payment default, breach of covenants, change of control, and material adverse effects. The Loan Agreement restricts certain activities, such as disposing of the Company’s business or certain assets, incurring additional debt or liens or making payments on other debt, making certain investments and declaring dividends, acquiring or merging with another entity, engaging in transactions with affiliates or encumbering intellectual property, among others. During the term of the Loan Agreement, the Company must maintain minimum unrestricted cash and cash equivalents equal to 5.0 times the average monthly cash burn measured over the trailing three-month period. Upon the occurrence of an event of default, a default interest rate of an additional 5 % per annum may be applied to the outstanding loan balances, and K2HV may declare all outstanding obligations immediately due and payable and exercise all of its rights and remedies as set forth in the Loan Agreement and under applicable law. The Company recorded $ 1.0 million, $ 1.9 million, $ 1.0 million, and $ 1.9 million in interest expense for the three and six months ended June 30, 2024 and 2023 , respectively. The effective interest rate on the Loan Agreement, including the amortization of the debt discount and issuance costs, and accretion of the Exit Fee, was 12.82 % at June 30, 2024. Future principal debt payments of the convertible term loans funded as of June 30, 2024 are as follows (in thousands): 2024 $ 3,427 2025 14,588 2026 11,985 Total principal payments 30,000 Plus: Final payment fee 1,800 Less: unamortized debt discount and final fee ( 1,352 ) Total debt 30,448 Less: current portion of long-term debt ( 10,336 ) Long-term debt, net $ 20,112 |
Net Loss Per Share
Net Loss Per Share | 6 Months Ended |
Jun. 30, 2024 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | 9. Net Loss Per Share Net Loss Per Share Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data): Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Numerator: Net loss $ ( 31,661 ) $ ( 24,045 ) $ ( 61,803 ) $ ( 46,608 ) Denominator: Weighted-average common shares outstanding, basic and diluted 113,425,357 47,208,664 104,150,625 35,717,309 Net loss per share, basic and diluted $ ( 0.28 ) $ ( 0.51 ) $ ( 0.59 ) $ ( 1.30 ) The 65,587,945 shares of the Company's common stock issuable upon exercise of the Pre-Funded Warrants described in Note 5 are included as outstanding common stock in the calculation of basic and diluted net loss per share. The Company has two classes of common stock, each with identical participation rights to earnings and liquidation preferences, and therefore the calculation of net loss per share as described above is identical to the calculation under the two-class method. The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: June 30, 2024 2023 Options to purchase common stock 12,804,957 11,718,296 Common stock issuable upon conversion of Loan Agreement 6,269,592 4,829,957 Potential shares issuable under the ESPP 69,617 - Total 19,144,166 16,548,253 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2024 | |
Accounting Policies [Abstract] | |
Recent Issued Accounting Pronouncements Not Yet Effective | Recent Issued Accounting Pronouncements Not Yet Effective In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, “Segment Reporting - Improvements to Reportable Segment Disclosures.” The ASU requires disclosure of incremental segment information on an annual and interim basis and also requires companies with a single reportable segment to provide all disclosures required by this ASU and all existing segment disclosures in Accounting Standard Codification (“ASC”) 280, “Segment Reporting.” The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” This ASU updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid by jurisdiction. This ASU is effective for annual periods beginning after December 15, 2024, and is applicable to the Company’s fiscal year beginning January 1, 2025, with early application permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Fair Value Disclosures [Abstract] | |
Schedule of Assets Carried at Fair Value on a Hierarchy Basis | The following tables set forth by level, within the fair value hierarchy, the assets carried at fair value (in thousands): Fair value measurements at June 30, 2024 using Active Observable Unobservable Total Cash Equivalents: Money market funds $ 73,543 $ - $ - $ 73,543 Government securities 161,061 - - 161,061 Marketable Securities: Government securities 55,517 - - 55,517 Total $ 290,121 $ - $ - $ 290,121 Fair value measurements at December 31, 2023 using Active Observable Unobservable Total Cash Equivalents: Money market funds $ 52,299 $ - $ - $ 52,299 Government securities 76,483 - - 76,483 Marketable Securities: Government securities 58,685 - - 58,685 Total $ 187,467 $ - $ - $ 187,467 |
Accrued Expenses and Other Cu_2
Accrued Expenses and Other Current Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses and Other Current Liabilities | Accrued expenses and other current liabilities consisted of the following (in thousands): June 30, December 31, 2024 2023 Accrued research and development $ 5,465 $ 3,537 Accrued employee compensation and benefits 3,525 5,478 Accrued consulting and professional services 719 1,026 Accrued legal services and license fee 852 250 Other 247 425 Total accrued expenses and other current liabilities $ 10,808 $ 10,716 |
Loan and Security Agreement (Ta
Loan and Security Agreement (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Debt Disclosure [Abstract] | |
Schedule of Future Principal Debt Payment | Future principal debt payments of the convertible term loans funded as of June 30, 2024 are as follows (in thousands): 2024 $ 3,427 2025 14,588 2026 11,985 Total principal payments 30,000 Plus: Final payment fee 1,800 Less: unamortized debt discount and final fee ( 1,352 ) Total debt 30,448 Less: current portion of long-term debt ( 10,336 ) Long-term debt, net $ 20,112 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Earnings Per Share [Abstract] | |
Summary of Basic and Diluted Net Loss Per Share | Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share data): Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Numerator: Net loss $ ( 31,661 ) $ ( 24,045 ) $ ( 61,803 ) $ ( 46,608 ) Denominator: Weighted-average common shares outstanding, basic and diluted 113,425,357 47,208,664 104,150,625 35,717,309 Net loss per share, basic and diluted $ ( 0.28 ) $ ( 0.51 ) $ ( 0.59 ) $ ( 1.30 ) |
Summary of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share | The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: June 30, 2024 2023 Options to purchase common stock 12,804,957 11,718,296 Common stock issuable upon conversion of Loan Agreement 6,269,592 4,829,957 Potential shares issuable under the ESPP 69,617 - Total 19,144,166 16,548,253 |
Nature of Business and Basis _2
Nature of Business and Basis of Presentation - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Organization Consolidation And Presentation Of Financial Statements [Line Items] | |||||
Date of incorporation | Apr. 17, 2018 | ||||
Net losses | $ 31,661 | $ 24,045 | $ 61,803 | $ 46,608 | |
Accumulated deficit | $ 309,400 | $ 309,400 | $ 247,597 |
Fair Value Measurements - Sched
Fair Value Measurements - Schedule of Assets Carried at Fair Value on a Hierarchy Basis (Details) - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 |
Assets, Fair Value Disclosure [Abstract] | ||
Total | $ 290,121 | $ 187,467 |
Government Securities | ||
Assets, Fair Value Disclosure [Abstract] | ||
Cash and cash equivalents fair value disclosure | 161,061 | 76,483 |
Marketable Securities, fair value disclosure | 55,517 | 58,685 |
Cash Equivalents - Money Market Funds | ||
Assets, Fair Value Disclosure [Abstract] | ||
Cash and cash equivalents fair value disclosure | 73,543 | 52,299 |
Active Markets (Level 1) | ||
Assets, Fair Value Disclosure [Abstract] | ||
Total | 290,121 | 187,467 |
Active Markets (Level 1) | Government Securities | ||
Assets, Fair Value Disclosure [Abstract] | ||
Cash and cash equivalents fair value disclosure | 161,061 | 76,483 |
Marketable Securities, fair value disclosure | 55,517 | 58,685 |
Active Markets (Level 1) | Cash Equivalents - Money Market Funds | ||
Assets, Fair Value Disclosure [Abstract] | ||
Cash and cash equivalents fair value disclosure | $ 73,543 | $ 52,299 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2024 | Dec. 31, 2023 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value, assets, level 1 to level 2 transfers | $ 0 | $ 0 |
Fair value, assets, level 2 to level 1 transfers | 0 | 0 |
Fair value, assets, transfers into level 3 | 0 | 0 |
Fair value, assets, transfers out of level 3 | 0 | 0 |
Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of long-term debt | $ 38,500 | $ 38,400 |
Accrued Expenses and Other Cu_3
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 |
Payables and Accruals [Abstract] | ||
Accrued research and development | $ 5,465 | $ 3,537 |
Accrued employee compensation and benefits | 3,525 | 5,478 |
Accrued consulting and professional services | 719 | 1,026 |
Accrued legal services and license fee | 852 | 250 |
Other | 247 | 425 |
Total accrued expenses and other current liabilities | $ 10,808 | $ 10,716 |
Stockholders' Equity - Addition
Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | 14 Months Ended | ||||||
Apr. 24, 2024 | Jun. 01, 2023 | May 16, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Dec. 31, 2023 | |
Class of Stock [Line Items] | |||||||||
Issuance of common stock, net of offering costs | $ 33,131 | $ 42,414 | $ 33,131 | $ 42,414 | |||||
Net proceeds from common stock and warrants after deducting underwriting discounts, commissions and other offering expenses | $ 161,400 | $ 134,700 | |||||||
Proceeds from issuance of pre-funded warrants, net of offering costs | 128,300 | 92,300 | 128,272 | 92,394 | |||||
Proceeds from issuance of common stock, net of offering costs | $ 33,100 | $ 42,400 | $ 33,131 | $ 42,600 | |||||
Voting Common Stock | |||||||||
Class of Stock [Line Items] | |||||||||
Common stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||
Voting Common Stock | Public Offering | |||||||||
Class of Stock [Line Items] | |||||||||
Sale of stock price per share | $ 2 | ||||||||
Voting Common Stock | Follow On Offering | |||||||||
Class of Stock [Line Items] | |||||||||
Number of shares issued | 4,958,068 | 23,287,134 | |||||||
Underwriter option to purchase number of additional shares | 2,485,487 | ||||||||
Sale of stock price per share | $ 7.13 | ||||||||
Voting Common Stock | ATM Program | Wedbush Securities, Inc. | |||||||||
Class of Stock [Line Items] | |||||||||
Number of shares issued | 0 | ||||||||
Issuance of common stock, net of offering costs | $ 75,000 | ||||||||
Common stock, par value | $ 0.0001 | ||||||||
Pre-Funded Warrants [Member] | |||||||||
Class of Stock [Line Items] | |||||||||
Common stock issuable upon exercise warrants | 65,587,945 | 65,587,945 | 65,587,945 | ||||||
Warrants exercised | 0 | 0 | 0 | ||||||
Warrant exercise price | $ 0.0001 | ||||||||
Pre-Funded Warrants [Member] | Voting Common Stock | |||||||||
Class of Stock [Line Items] | |||||||||
Common stock issuable upon exercise warrants | 18,577,419 | 47,010,526 | |||||||
Common stock price per warrant | $ 7.1299 | $ 1.9999 | |||||||
Warrant exercise price | $ 0.0001 | $ 0.0001 |
Collaboration and License Agr_2
Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||||||
May 08, 2023 | Jul. 31, 2023 | Mar. 31, 2020 | Jun. 30, 2024 | Jun. 30, 2023 | Mar. 31, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Collaboration And License Agreements [Line Items] | |||||||||
Collaboration and license revenue | $ 536 | $ 3,148 | $ 1,102 | $ 9,951 | |||||
Long-term deferred revenue | 3,955 | 3,955 | $ 5,622 | ||||||
Novartis | |||||||||
Collaboration And License Agreements [Line Items] | |||||||||
License agreement date | Mar. 31, 2020 | ||||||||
Collaboration and license revenue | $ 5,800 | ||||||||
Amgen Inc. | Amgen Agreement | |||||||||
Collaboration And License Agreements [Line Items] | |||||||||
License agreement date | May 08, 2023 | ||||||||
Upfront payment receivable | $ 30,000 | ||||||||
Upfront payment received | $ 30,000 | ||||||||
Potential milestone payment | $ 500,000 | ||||||||
Expects research term | 3 years | ||||||||
Collaboration and license revenue | 500 | $ 3,100 | 1,100 | $ 3,100 | |||||
Deferred revenue | 14,700 | 14,700 | |||||||
Long-term deferred revenue | $ 4,000 | $ 4,000 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Details) | Jun. 30, 2018 |
Royalty Agreement | |
Commitments And Contingencies Disclosure [Line Items] | |
Percentage of aggregate royalty of net sales of any product sold | 1% |
Loan and Security Agreement - A
Loan and Security Agreement - Additional Information (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Sep. 09, 2022 | Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Debt Instrument [Line Items] | |||||
Debt instrument drew | $ 30,000,000 | $ 30,000,000 | |||
Interest rate | 12.82% | ||||
Default interest rate | 5% | ||||
Interest expense | 1,000,000 | $ 1,000,000 | $ 1,900,000 | $ 1,900,000 | |
K2HV [Member] | |||||
Debt Instrument [Line Items] | |||||
Principal amount | $ 60,000,000 | ||||
Facility fee | $ 400,000 | ||||
Additional principal amount percentage | 1% | ||||
Term loan maturity date | Sep. 01, 2026 | ||||
Interest only payment term | 24 months | ||||
Interest only payment extended term | 36 months | ||||
Contractual interest rate | 8.75% | ||||
Interest rate | 9.90% | 9.90% | |||
Conversion price | $ 4.785 | ||||
Final fee | 6% | ||||
Covenant terms | During the term of the Loan Agreement, the Company must maintain minimum unrestricted cash and cash equivalents equal to 5.0 times the average monthly cash burn measured over the trailing three-month period. | ||||
K2HV [Member] | Prime Rate [Member] | |||||
Debt Instrument [Line Items] | |||||
Prime rate | 4.75% | ||||
Tranche One [Member] | K2HV [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt instrument drew | $ 30,000,000 | ||||
Tranche Two [Member] | K2HV [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt instrument remaining borrowing capacity | 10,000,000 | ||||
Tranche Three [Member] | K2HV [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt instrument remaining borrowing capacity | $ 20,000,000 | ||||
Maximum [Member] | K2HV [Member] | |||||
Debt Instrument [Line Items] | |||||
Prepayment fee range | 4% | ||||
Minimum [Member] | K2HV [Member] | |||||
Debt Instrument [Line Items] | |||||
Prepayment fee range | 1% | ||||
Covenant Terms, Unrestricted Cash and Cash Equivalents | $ 5,000,000 | $ 5,000,000 |
Loan and Security Agreement - S
Loan and Security Agreement - Schedule of Future Principal Debt Payment (Details) - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 |
Debt Disclosure [Abstract] | ||
2024 | $ 3,427 | |
2025 | 14,588 | |
2026 | 11,985 | |
Total principal payments | 30,000 | |
Plus: Final payment fee | 1,800 | |
Less: unamortized debt discount and final fee | (1,352) | |
Total debt | 30,448 | |
Less: current portion of long-term debt | (10,336) | $ (3,347) |
Long-term debt, net | $ 20,112 | $ 26,700 |
Net Loss Per Share - Summary of
Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Earnings Per Share [Abstract] | ||||
Net loss | $ (31,661) | $ (24,045) | $ (61,803) | $ (46,608) |
Weighted-average common shares outstanding, basic | 113,425,357 | 47,208,664 | 104,150,625 | 35,717,309 |
Weighted-average common shares outstanding, diluted | 113,425,357 | 47,208,664 | 104,150,625 | 35,717,309 |
Net loss per share, basic | $ (0.28) | $ (0.51) | $ (0.59) | $ (1.3) |
Net loss per share, diluted | $ (0.28) | $ (0.51) | $ (0.59) | $ (1.3) |
Net Loss Per Share - Additional
Net Loss Per Share - Additional Information (Details) | Jun. 30, 2024 shares |
Pre-Funded Warrants [Member] | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |
Common stock issuable upon exercise warrants | 65,587,945 |
Net Loss Per Share - Summary _2
Net Loss Per Share - Summary of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share (Details) - shares | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Total | 19,144,166 | 16,548,253 |
Options to Purchase Common Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Total | 12,804,957 | 11,718,296 |
Common stock issuable upon conversion of Loan Agreement | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Total | 6,269,592 | 4,829,957 |
Potential shares issuable under the ESPP | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Total | 69,617 |